Hormonal

Pasireotide

Also known as: Signifor, Signifor LAR

FDA Approved
Share:

Key Facts: Pasireotide

Category
Hormonal
FDA Status
FDA Approved
Clinical Status
FDA Approved - Cushing's disease and acromegaly
Administration
Subcutaneous or intramuscular
Typical Dose
300-900 mcg twice daily
Frequency
Twice daily (SC) or monthly (LAR)
Duration
Long-term / chronic use
Also Known As
Signifor, Signifor LAR

Mechanism of Action

Pasireotide binds four of the five somatostatin receptors (SSTR1, 2, 3, and 5) and, unlike the older analogs, has its highest affinity for SSTR5 rather than SSTR2. That matters because the corticotroph tumors of Cushing's disease are loaded with SSTR5, so pasireotide can suppress their ACTH output and bring cortisol down where octreotide-style drugs fail. In acromegaly it engages both SSTR2 and SSTR5 on growth-hormone-secreting tumors. The downside comes from the same receptor breadth: hitting somatostatin receptors on the pancreas and gut blunts insulin and the incretin hormones GLP-1 and GIP, which is the proposed mechanism behind its frequent hyperglycemia. So the trait that makes it effective is also what makes it tricky to dose.

Research Summary

Pasireotide rests on real randomized human trials. The pivotal 12-month phase 3 study in Cushing's disease, published by Colao and colleagues in the New England Journal of Medicine in 2012, randomized 162 patients and normalized urinary free cortisol in roughly 15 to 26 percent depending on dose, with broad declines in cortisol and symptom improvement. In acromegaly, the phase 3 PAOLA trial showed pasireotide LAR achieved biochemical control in 15 to 20 percent of patients who had failed octreotide or lanreotide, versus 0 percent who stayed on those older drugs. The recurring and clinically important finding across trials is hyperglycemia: well over half of patients develop elevated blood glucose, and many need glucose-lowering medication, driven by suppressed insulin and incretin secretion. So the evidence is strong on efficacy in tough cases and equally clear on the metabolic trade-off.

Trial Progress:FDA Approved
Pre
I
II
III
IV
FDA

Dosing Information

FDA Approved·Human clinical trials completed, FDA approved

Typical Dosing

Community experience

Common Dose

300-900 mcg twice daily

Range

300-900 mcg per dose

Frequency

Twice daily (SC) or monthly (LAR)

Somatostatin analog for Cushing's disease. Higher hyperglycemia risk than other somatostatins.

Research Dosing

Scientific studies

FDA-approved dosing

Doses from Studies

Duration

Long-term / chronic use

Administration

Subcutaneous or intramuscular

Timing & Administration

Best Time to Take

Morning or as directed

Follow recommended protocol

Food Recommendation

With or without food

Why This Timing?

Timing may vary based on individual response and goals. Consistency is generally more important than specific timing.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • Hyperglycemia and diabetes (very common)
  • Diarrhea
  • Nausea
  • Gallstones
  • QT prolongation (serious)
  • Liver enzyme elevations
  • Adrenal insufficiency
  • FDA approved (Signifor)

References

Research This Peptide Further

Frequently Asked Questions

What does Pasireotide do?

Pasireotide (brand name Signifor) is a second-generation somatostatin analog, a cyclic six-amino-acid peptide engineered to hit more receptor subtypes than octreotide or lanreotide. Its standout use is Cushing's disease, where it was the first drug FDA-approved (2012) to directly target the pituitary tumor driving cortisol excess, and it is also approved for acromegaly that resists first-line analogs. The catch is real and well known: it raises blood sugar in most patients, so it is a powerful but high-maintenance option.

How does Pasireotide work?

Pasireotide binds four of the five somatostatin receptors (SSTR1, 2, 3, and 5) and, unlike the older analogs, has its highest affinity for SSTR5 rather than SSTR2. That matters because the corticotroph tumors of Cushing's disease are loaded with SSTR5, so pasireotide can suppress their ACTH output and bring cortisol down where octreotide-style drugs fail. In acromegaly it engages both SSTR2 and SSTR5 on growth-hormone-secreting tumors. The downside comes from the same receptor breadth: hitting somatostatin receptors on the pancreas and gut blunts insulin and the incretin hormones GLP-1 and GIP, which is the proposed mechanism behind its frequent hyperglycemia. So the trait that makes it effective is also what makes it tricky to dose.

Is Pasireotide FDA approved?

Yes, Pasireotide is FDA approved. FDA Approved - Cushing's disease and acromegaly

What are the side effects of Pasireotide?

Reported side effects include: Hyperglycemia and diabetes (very common), Diarrhea, Nausea, Gallstones, QT prolongation (serious). Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of Pasireotide?

Community-reported common dose: 300-900 mcg twice daily (Twice daily (SC) or monthly (LAR)). Range: 300-900 mcg per dose. Administration: Subcutaneous or intramuscular. Community-reported doses. Not medical advice. Consult healthcare provider.

Related Peptides

Peptides commonly compared with Pasireotide or used in similar applications.

Octreotide

FDA

Octreotide is a synthetic eight-amino-acid mimic of the natural hormone somatostatin, the body's main 'off switch' for hormone secretion. It shuts down excess growth hormone, so it is a frontline FDA-approved drug for acromegaly, and it also tames the flushing and diarrhea of hormone-secreting carcinoid and other neuroendocrine tumors. This is real, approved medicine with decades of clinical data behind it, sold as Sandostatin (injectable, since 1988), Sandostatin LAR (monthly depot), and Mycapssa (oral capsule, approved 2020).

Hormonal

Insulin

FDA

Insulin is the body's main blood-sugar-lowering hormone, a 51-amino-acid protein made of two chains (a 21-residue A-chain and a 30-residue B-chain) held together by disulfide bonds. Secreted by the beta cells of the pancreas, it tells the liver, muscle, and fat to take up glucose and store energy. Discovered in 1921 and first given to a patient in January 1922, it remains one of the most consequential drugs in medicine and is the cornerstone of treatment for type 1 and many cases of type 2 diabetes.

Hormonal

Glucagon

FDA

Glucagon is insulin's counterweight, a 29-amino-acid peptide hormone secreted by the alpha cells of the pancreas that raises blood sugar instead of lowering it. When glucose drops, glucagon tells the liver to break down stored glycogen and make new glucose, pushing blood sugar back up. Medically it is the emergency rescue treatment for severe hypoglycemia (the kind that knocks out a person with diabetes), available as injectable kits and a nasal-spray form, and it is also used in some diagnostic imaging to relax the gut.

Hormonal

Oxytocin

FDA

Oxytocin is a 9-amino-acid hormone made in the hypothalamus, famous as the chemistry behind labor contractions, breastfeeding, and social bonding. As an injectable drug it is FDA-approved to induce labor and control postpartum bleeding, but the intranasal 'love hormone' versions sold for trust, anxiety, and autism are experimental and the human results are genuinely mixed. The hype runs well ahead of the evidence.

Hormonal

Gonadorelin

FDA

Gonadorelin is a synthetic copy of natural GnRH (gonadotropin-releasing hormone), a 10-amino-acid peptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) that tells the pituitary to release LH and FSH. It is FDA-approved for evaluating pituitary function and has historical use in inducing ovulation. In the peptide world it is mostly used off-label to keep the testes working during testosterone replacement, and the catch is that timing matters enormously: pulse it and you stimulate, give it continuously and you shut the system down.

Hormonal

Leuprolide

FDA

Leuprolide (brand name Lupron) is a synthetic GnRH agonist, a modified peptide about 20 times more potent than natural GnRH, and it is FDA-approved for advanced prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. The clever part is counterintuitive: it works by overstimulating the GnRH system so hard that the pituitary shuts down sex hormone production. It is a real, long-established prescription drug, not a research peptide, and it carries meaningful side effects from the low-hormone state it creates.

Hormonal

Want updates on Pasireotide research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.